Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form

Journal of Pharmaceutical Sciences

Volumn 101, Issue 1, 2012, Pages 342-353

  Puri, Vibha ^a   Dantuluri, Ajay K ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Amorphous; Celecoxib; Coating; Dissolution; Physical stability; Solid dispersion; Surface modification

Indexed keywords

EXCIPIENT; INULIN; MICROCRYSTALLINE CELLULOSE; POLYVINYL ACETATE; POLYVINYL ALCOHOL;

ARTICLE; CRYSTALLIZATION; DRUG COATING; DRUG RELEASE; ENTHALPY; PERMEABILITY BARRIER;

EID: 82255175810     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22743     Document Type: Article

References (58)

1. Janssens S, Van den Mooter G. 2009. Review: Physical chemistry of solid dispersions. J Pharm Pharmacol 61:1571-1586.
2. Qian F, Huang J, Hussain MA. 2010. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci 99:2941-2947.
3. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48:27-42.
4. Serajuddin ATM. 1999. Solid dispersions of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
5. Sethia S, Squillante E. 2003. Solid dispersions: Revival with greater possibilities and applications in oral drug delivery. Crit Rev Ther Drug Carrier Syst 20:217-249.
6. Drooge DJV, Hinrichs WLJ, Frijlink HW. 2004. Anomalous dissolution behavior of tablets prepared from sugar glass-based solid dispersions. J Control Release 97:441-452.
7. Ford JL, Rubinstein MH. 1980. Formulation and aging of tablets prepared from indomethacin-poly(ethylene glycol) 6000 solid dispersions. Pharm Acta Helv 55:1-7.
8. Serajuddin AT, Sheen PC, Mufson D, Bernstein DF, Augustine MA. 1988. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J Pharm Sci 77:414-417.
9. Fan C, Pai-Thakur R, Phuapradit W, Zhang L, Tian H, Malick W, Shah N, Kislalioglu MS. 2009. Impact of polymers on dissolution performance of an amorphous gelleable drug from surface-coated beads. Eur J Pharm Sci 37:1-10.
10. Ghebremeskel AN, Vemavarapu C, Lodaya M. 2006. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Stability testing of selected solid dispersions. Pharm Res 23:1928-1936.
11. Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, Gupta V, Ma C, Mahajan N, Akrami A, Surapaneni S. 2008. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: A case study. Mol Pharm 5:981-993.
12. Hageman MJ, He X, Kararli TT, Mackin LA, Mackin PJ, Rohrs BR, Stefanski KJ. 2005. Solid-state form of celecoxib having enhanced bioavailability. Patent US6964978.
13. Kajiyama T, Tanaka K, Takahara A. 1998. Study of the surface glass transition behaviour of amorphous polymer film by scanning-force microscopy and surface spectroscopy. Polymers 39:4665-4673.
14. Sharp JS, Forest JA. 2003. Free surface cause reductions in the glass transition temperature of thin polystyrene films. Phys Rev Lett 91:235701.
15. Yang Z, Fujii Y, Lee FK, Lam CH, Tsui OKC. 2010. Glass transition dynamics and surface layer mobility in unentangled polystyrene films. Science 328:1676-1679.
16. Dutcher JR, Ediger MD. 2008. Glass surfaces not so glassy. Science 319:577-578.
17. Jukes PC, Das A, Durell M, Trolley D, Higgins AM, Geoghegan M, Macdonald JE, Jones RAL, Brown S, Thompson P. 2005. Kinetics of surface crystallization in thin films of poly(ethylene terephthalate). Macromolecules 38:2315-2320.
18. g. Pharm Res 23:2350-2355.
19. g Pharm Res 27:1558-1567.
20. Zhu L, Wong L, Yu L. 2008. Surface-enhanced crystallization of amorphous nifedipine. Mol Pharm 5:921-926.
21. Kearns KL, Ediger MD, Huth H, Schick C. 2010. One micrometer length scale controls kinetic stability of low-energy glasses. J Phys Chem Lett 1:388-392.
22. Wu T, Sun Y, Li N, de Villiers MM, Yu L. 2007. Inhibiting surface crystallization of amorphous indomethacin by nanocoating. Langmuir 23:5148-5153.
23. Bosselmann S, Owens DE 3rd, Kennedy RL, Herpin MJ, Williams RO 3rd. 2010. Plasma deposited stability enhancement coating for amorphous ketoprofen. Eur J Pharm Biopharm 78:67-74.
24. Bruce CD, Fegely KA, Rajabi-Siahboomi AR, McGinity JW. 2010. Aqueous film coating to reduce recrystallization of guaifenesin from hot-melt extruded acrylic matrices. Drug Dev Ind Pharm 36:218-226.
25. Buckton G. 1995. Interfacial phenomena in drug delivery and targeting. Switzerland: Harwood Academic Publishers.
26. Kaushal A, Chakraborti AK, Bansal AK. 2008. FTIR studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs. Mol Pharm 5:937-945.
27. Puri V, Dantuluri AK, Kumar M, Karar N, Bansal AK. 2010. Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug. Eur J Pharm Sci 40:84-93.
28. Gilis PMV, Conde VFVD, Vandecruys RPG. 1997. Beads having a core coated with an antifungal and a polymer. Patent US5633015.
29. Bhugra C, Pikal MJ. 2008. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97:1329-1349.
30. Kaushal AM, Gupta P, Bansal AK. 2004. Amorphous drug delivery systems: Molecular aspects, design and performance. Crit Rev Ther Drug Carrier Syst 21:133-193.
31. Gupta P, Bansal AK. 2005. Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility. Pharmazie 60:830-836.
32. Gupta P, Bansal AK. 2006. Oral bioavailability advantage from stabilized amorphous systems of celecoxib. J Pharm Res 5:15-24.
33. Puri V, Dhantuluri AK, Bansal AK. 2011. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion. J Pharm Sci 100:2460-2468.
34. He W, Yang M, Fan JH, Feng CX, Zhang SJ, Wang JX, Guan PP, Wu W. 2010. Influences of sodium carbonate on physicochemical properties of lansoprazole in designed multiple coating pellets. AAPS PharmSciTech 11:1287-1293.
35. Gupta P, Bansal AK. 2005. Spray drying for generation of a ternary amorphous system of celecoxib, PVP and meglumine. Pharm Dev Technol 10:273-281.
36. Gupta P, Bansal AK. 2005. Molecular interactions in celecoxib-PVP-meglumine amorphous system. J Pharm Pharmacol 57:303-310.
37. Hodge IM. 1994. Enthalpy relaxation and recovery in amorphous materials. J Non Cryst Solids 169:211-266.
38. Laksmana FL, Vliet LJV, Kok PJAH, Vromans H, Frijlink HW, Maarschalk KVV. 2009. Quantitative image analysis for evaluating the coating thickness and pore distribution in coated small particles. Pharm Res 26:965-976.
39. Accessed December 10, 2009, at: http://www.accessdata.fda.gov/scripts/cder/dissolution/.
40. ICH guidance for industry: dissolution testing of immediate release solid oral dosage forms. 1997. Rockville, Maryland.
41. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
42. Hancock BC, Shamblin SL. 2000. Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetry. Thermochim Acta 380:95-107.
43. Aso Y, Yoshioka S, Kojima S. 2004. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions. J Pharm Sci 93:384-391.
44. Bansal SS, Kaushal AM, Bansal AK. 2008. Co-relationship of physical stability of amorphous dispersions with enthalpy relaxation. Pharmazie 63:812-814.
45. Korhonen O, Bhugra C, Pikal MJ. 2008. Correlation between molecular mobility and crystal growth of amorphous phenobarbital and phenobarbital with polyvinylpyrrolidone and l-proline. J Pharm Sci 97:3830-3841.
46. Vyazovkin S, Dranca I. 2007. Effect of physical aging on nucleation of amorphous indomethacin. J Phys Chem 111:7283-7287.
47. Efremov MY, Olson EA, Zhang M, Zhang Z, Allen LH. 2003. Glass transition in ultrathin polymer films: Calorimetric study. Phys Rev Lett 91:085703.
48. Muskulus F, Kraa P, Burgenmeister A. 2010. Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation. Patent US7332474.
49. Steele DF, Edge S, Tobyn MJ, Moreton RC, Staniforth JN. 2003. Adsorption of an amine drug onto microcrystalline cellulose and silicified microcrystalline cellulose samples. Drug Dev Ind Pharm 29:475-487.
50. Rowe RC, Sheskey PJ, Quinn ME, Eds. 2009. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press and American Pharmacists Association.
51. Buttini F, Soltani A, Colombo P, Marriott C, Jones SA. 2008. Multilayer PVA adsorption onto hydrophobic drug substrates to engineer drug-rich microparticles. Eur J Pharm Sci 33:20-28.
52. Traynora MJ, Zhaob Y, Browna MB, Jones SA. 2011. Vinyl polymer-coated lorazepam particles for drug delivery to the airways. Int J Pharm 410:9-16.
53. Chawla G, Bansal AK. 2008. Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-polymeric hydrophilic additives. Acta Pharm 58:257-274.
54. Mwesigwa E, Buckton G, Basit AW. 2005. The hygroscopicity of moisture barrier film coatings. Drug Dev Ind Pharm 31:959-968.
55. DiNunzio JC, Miller DA, Yang W, McGinity JW, Williams III RO. 2008. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. Mol Pharmaceutics 5:968-980.
56. Erickson M, Josefsson L. 2000. Pharmaceutical formulation of omeprazole. Patent US6090827.
57. Kinoshita M, Baba K, Nagayasu A, Yamabe K, Shimooka T, Takeichi Y, Azuma M, Houchi H, Minakuchi K. 2002. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci 91:362-370.
58. Kumar V, Yang T, Yang Y. 1999. Interpolymer complexation. I. Preparation and characterization of a polyvinyl acetate phthalate-polyvinylpyrrolidone (PVAP-PVP) complex. Int J Pharm 188:221-232.